David Ledger

Healthcare Industry Commercial Advisor | Analytics Driven Business Insights | Cyclist

[David Ledger @Varese_Group]

Today's headline is the deals trio. Roche signed a $700M upfront, up-to-$2.3B pact for Nurix's brain-penetrant BTK degrader bexobrutideg. Johnson & Johnson agreed to acquire Firefly Bio for $1B in cash for its degrader-antibody conjugate platform. Incyte will pay $1.25B upfront and up to $2B total for Vega Therapeutics's first-in-class anti-Protein S antibody in Phase 3 von Willebrand disease. That is the densest M&A day of the quarter and a clear bet by three top-10 names on the next wave of protein-degradation and rare-disease modality plays. Sanofi's Sarclisa subcutaneous became the first EU anticancer therapy delivered through an on-body injector, AbbVie pre-released Phase 3 epcoritamab data ahead of EHA 2026 with a hazard ratio of 0.74 versus chemoimmunotherapy in relapsed LBCL, and Novartis previewed the Phase 3 RemIND late-breaker for Rhapsido in chronic inducible urticaria at EAACI 2026. The full ADA 2026 and ERA 2026 weekend readouts ran in yesterday's Monday 8 June edition.
Check out the latest article in my newsletter: Pharma Daily News Roundup - Powered by Varese Group https://t.co/8O7FR5ebOj via @LinkedIn

[David Ledger @Varese_Group]

If you read one story this week, make it Medtronic's three 510(k) filings to push Hugo into general and gynecologic surgery in the United States. Hugo has been a urology story since its December 2025 clearance; with these submissions Medtronic is signalling it is ready to fight Intuitive Surgical on the part of the soft-tissue robotics market that actually matters commercially. The week's other through-line is platform consolidation: Insulet locks in Abbott Libre 3 Plus on Omnipod 5, ResMed closes Noctrix to add tonic motor activation to its sleep portfolio, and Fresenius Medical Care moves home dialysis onto a single connected backbone with kinexus.
Check out the latest article in my newsletter: MedTech Weekly News Roundup - Powered by Varese Group https://t.co/ut2z23vpVp via @LinkedIn

[David Ledger @Varese_Group]

If you read one story this week, make it Nestlé's lactoferrin partnership with Helaina. Nestlé is locking in multi-year R&D on a recombinant human-identical lactoferrin called effera, and that puts the world's largest infant formula maker into the bioactives race Reckitt MJN, Danone and Feihe are all sprinting toward. Lactoferrin has gone from premium claim to category requirement in roughly 36 months, and the bovine supply chain that delivered the first wave will not scale to the next. Whoever locks in recombinant supply in 2026 owns the formulation arms race for the next decade. The week's other through-line is active nutrition consolidation. Lactalis bought UK protein brand Protein Works (~£55m revenue), and on the same day Applied Nutrition picked up Buffalo-based Nutrablend for $16m. Two very different companies, opposite ends of the dairy-to-sports continuum, both deciding active nutrition is the place to be.
Check out the latest article in my newsletter: Consumer Health Weekly News Roundup - Powered by Varese Group https://t.co/LUhNoujHCa via @LinkedIn

[David Ledger @Varese_Group]

If you read one story this week, make it Bayer's finerenone double feature. The FDA approved Kerendia for heart failure with LVEF ≥40% on June 5, the same day the Phase 3 FIND-CKD readout in non-diabetic chronic kidney disease was published in NEJM. One drug, two pivotal milestones, one day. Kerendia now has a CV indication spanning the part of the heart failure spectrum where no MRA has previously demonstrated benefit, and a non-diabetic CKD case strong enough to sit alongside the FIDELIO/FIGARO foundation. The other story shape of the week was ADA 2026 in New Orleans, where Pfizer (VESPER-3), Boehringer Ingelheim (SYNCHRONIZE-1), Novo Nordisk (CagriSema and zenagamtide), MannKind (Afrezza pediatric), Structure Therapeutics (aleniglipron) and Innovent (mazdutide) all dropped data into a single conference window. The GLP-1 field is no longer a two-horse race even if Lilly and Novo still hold the commercial book.
Check out the latest article in my newsletter: Pharma Weekly News Roundup - Powered by Varese Group https://t.co/on9arltt3K via @LinkedIn

[David Ledger @Varese_Group]

Today's headline is Gilead's lenacapavir launch in South Africa. South Africa carries the largest HIV burden in the world, and this is the first time twice-yearly injectable PrEP has reached frontline public clinics in any high-incidence country, ahead of the broader generic rollout Gilead has lined up across 120 low- and lower-middle-income countries. Two other items round out a quiet Friday: Lundbeck's bocunebart cleared its Phase IIb primary endpoint in migraine prevention at AHS 2026, opening a credible non-CGRP path in a category that has lacked a new mechanism for a decade. Lupin won FDA approval for Ranluspec, the only interchangeable ranibizumab biosimilar offered in both vials and pre-filled syringes across both Lucentis strengths.
https://t.co/MRuZWTrtPm via @LinkedIn

[David Ledger @Varese_Group]

Today's headline is Innovent Biologics' IBI343. A Phase 3 readout in late-line CLDN18.2-positive gastric cancer and a China NMPA NDA acceptance, both announced the same day, make it the first CLDN18.2 antibody-drug conjugate to enter formal regulatory review anywhere in the world. Takeda holds ex-Greater China rights under a deal signed in 2024, so this is also a major value point for one of big pharma's most-watched external oncology bets. The day's other two stories sit in autoimmune and rare disease. UCB and Biogen presented Week 48 PHOENYCS GO data at EULAR 2026 showing dapirolizumab pegol cut severe flares and let patients taper glucocorticoids without losing disease control, the second clean Phase 3 win in systemic lupus inside a fortnight after Johnson & Johnson's nipocalimab. And Biogen secured FDA Breakthrough Therapy Designation for salanersen, a once-yearly intrathecal antisense oligonucleotide for SMA that is now positioned to succeed, and in time displace, Biogen's own Spinraza.
https://t.co/8jpyvaJipe

[David Ledger @Varese_Group]

Today's headline is Johnson & Johnson's nipocalimab. A Phase 2 win in systemic lupus, sustained out to 52 weeks, is the first time an FcRn blocker has shown disease-modifying activity in SLE. That widens the franchise well beyond myasthenia gravis and gives J&J a credible challenger to Benlysta and Saphnelo in a category that has resisted new mechanisms for two decades. EULAR 2026 in London also delivered the first full open-label extension year for Amgen's Uplizna in IgG4-related disease, with zero flares on continued therapy. And Eli Lilly went deep into RNA medicines with an up-to-$1.9 billion Ascidian collaboration for monogenic kidney diseases, the largest publicly disclosed RNA exon-editing deal to date.
Pharma Daily News Roundup - Powered by Varese Group https://t.co/Lo7bNU11QW

[David Ledger @Varese_Group]

Check out the latest article in my newsletter: Pharma Daily News Roundup - Powered by Varese Group https://t.co/00Kfn6EY2d via @LinkedIn

[David Ledger @Varese_Group]

https://t.co/Dryexn3oXN

[David Ledger @Varese_Group]

If you read one story this week, make it the Arla/DMK merger, effective today. Europe's largest farmer-owned dairy cooperative came into existence at midnight: €20 billion in revenue, 11,200 farmers, seven countries. Every infant formula and clinical nutrition brand sourcing European dairy just woke up to a more consolidated upstream. Read it alongside Fonterra completing its Mainland consumer dairy exit to Lactalis in the same week, and you have two major dairy companies moving in opposite directions. Arla is growing by merger; Fonterra is shrinking to B2B. The brands caught in the middle, sourcing European dairy ingredients, have fewer good alternatives than they had a month ago. Separately: Unilever is spending $270 million on a wellbeing innovation centre explicitly built around Nutrafol, Liquid I.V., and OLLY. Rohto has declared itself a longevity company. This is no longer VMS as a brand extension strategy. It is starting to look like a category with genuine institutional conviction behind it.
Check out the latest article in my newsletter: Consumer Health Weekly News Roundup - Powered by Varese Group https://t.co/k5rlc7xNld via @LinkedIn

[David Ledger @Varese_Group]

If you read one story this week, make it Abbott's ASCO debut as a diagnostics powerhouse. Three months after closing the Exact Sciences acquisition, Abbott walked into Chicago with 11 abstracts spanning early detection, residual disease monitoring, and screening, the clearest signal yet that the combined entity intends to own the full cancer diagnostics continuum. Elsewhere, a quieter week saw Insulet manage its second pod correction of 2026, Philips bring Disney into the MRI suite, and Fresenius Medical Care preview its digital home-dialysis platform ahead of ERA.
Check out the latest article in my newsletter: MedTech Weekly News Roundup - Powered by Varese Group https://t.co/rp4mYgM3Qk via @LinkedIn

[David Ledger @Varese_Group]

If you read one story this week, make it Revolution Medicines' ASCO plenary. Daraxonrasib nearly doubled overall survival in metastatic pancreatic cancer, a disease where incremental gains have been the best anyone could manage for decades. The result (13.2 vs 6.7 months median OS, HR 0.40) will reshape how oncologists think about targeted therapy in this tumour type, and it earned a simultaneous NEJM publication. ASCO 2026 ran the full week: Lilly's Retevmo cut adjuvant lung cancer recurrence by 83% (also plenary), BMS brought the first Phase 3 win for its CELMoD platform in myeloma, and J&J pushed RYBREVANT into head and neck cancer with a 42% response rate. Four FDA approvals and a trio of Lilly acquisitions round out a packed seven days.
Check out the latest article in my newsletter: Pharma Weekly News Roundup - Powered by Varese Group https://t.co/Hihoxi346U via @LinkedIn

[David Ledger @Varese_Group]

Today's headline is Bristol Myers Squibb's late-breaking SUCCESSOR-2 readout at ASCO, where mezigdomide cut the risk of progression or death by more than half in relapsed multiple myeloma. It is the first positive Phase 3 for a CELMoD agent, the molecule class BMS has been building its post-Revlimid identity around. Separately, MannKind secured FDA approval for inhaled insulin in children aged six and older: a needle-free first that rewrites the paediatric diabetes treatment experience.
Check out the latest article in my newsletter: Pharma Daily News Roundup - Powered by Varese Group https://t.co/RyjL1B2yVm via @LinkedIn

[David Ledger @Varese_Group]

Today's headline is GSK's pivotal Phase 3 readout for bepirovirsen, which achieved a 19% functional cure rate in chronic hepatitis B versus zero on placebo and was published simultaneously in the New England Journal of Medicine. If that number sounds modest, consider the baseline: the current standard of care cures fewer than 1% of patients and typically requires lifelong therapy. For a disease affecting over 240 million people worldwide, this is the most significant treatment advance in decades.
Check out the latest article in my newsletter: Pharma Daily News Roundup - Powered by Varese Group https://t.co/jLzIY8G81o via @LinkedIn

[David Ledger @Varese_Group]

Pharma Daily News Roundup - Powered by Varese Group https://t.co/BEA7eOSM9E

[David Ledger @Varese_Group]

Check out my latest Consumer Health Weekly News Roundup - Powered by Varese Group https://t.co/Nw73K7rdYL

[David Ledger @Varese_Group]

Check out the latest article in my newsletter: MedTech Weekly News Roundup - Powered by Varese Group https://t.co/e0wABUe5TV

[David Ledger @Varese_Group]

Check out the latest article in my newsletter: Pharma Daily News Roundup - Powered by Varese Group https://t.co/BEA7eOSM9E via @LinkedIn

[David Ledger @Varese_Group]

NICE recommends remote monitoring technology for heart failure patients https://t.co/NZHTbTK39J